JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2002; 40:652-661
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marso, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marso, S. P.

Optimizing the diabetic formulary: beyond aspirin and insulin

Steven P. Marso, MD, FACC*,*

* Mid America Heart Institute, Saint Luke’s Hospital, Kansas City, Missouri, USA



View larger version (22K):

[in a new window]
  		Figure 1 The survival curves for the depicted disease states are shown. Data are derived from the National Center for Health Statistics. This figure was adapted with permission from reference 4.

 


View larger version (17K):

[in a new window]
  		Figure 2 This bar graph depicts the lifetime costs associated with the successful implementation of two blood pressure goals. This model was derived using a 60-year-old diabetic hypertensive patient with no prior history of cardiovascular or end-stage renal disease. This figure was adapted with permission from reference 50. ESRD = end-stage renal disease; HF = heart failure; MI = myocardial infarction.

 


View larger version (18K):

[in a new window]
  		Figure 3 The Kaplan-Meier estimates for all-cause mortality for the diabetic patients enrolled in MICRO-HOPE are shown. Figure reproduced with permission from reference 57.

 


View larger version (25K):

[in a new window]
  		Figure 4 One-year Kaplan-Meier estimates of the invasive treatment arms for the patients with diabetes mellitus enrolled in Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) are shown. A = the rate of death or myocardial infarction (MI) within EPISTENT; B = the 1-year target vessel revascularization (TVR) rates. PTCA = percutaneous transluminal coronary angioplasty.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.